Prime Medicine Common Stock Net 2021-2024 | PRME

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Prime Medicine common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Prime Medicine common stock net from 2021 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$231.2B
Amgen (AMGN)	$160B
Gilead Sciences (GILD)	$137.1B
Vertex Pharmaceuticals (VRTX)	$123.3B
Bristol Myers Squibb (BMY)	$113.2B
CSL (CSLLY)	$80.1B
GSK (GSK)	$76.6B
Regeneron Pharmaceuticals (REGN)	$76.1B
Argenex SE (ARGX)	$39.3B
Alnylam Pharmaceuticals (ALNY)	$32.5B
BioNTech SE (BNTX)	$28.3B
BeiGene (ONC)	$23.9B
Biogen (BIIB)	$20.1B
Illumina (ILMN)	$15.4B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.9B
Genmab (GNMSF)	$14.7B
Incyte (INCY)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
BioMarin Pharmaceutical (BMRN)	$13.1B
Moderna (MRNA)	$13B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Sarepta Therapeutics (SRPT)	$10.4B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.3B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.2B
Repligen (RGEN)	$9.1B
Bio-Rad Laboratories (BIO.B)	$8.7B